Clinical Trial Update: CER-001 Atherosclerosis Regression ACS Trial [Phase 2]

View source ↗

Summary

Phase 2 trial CER-001 for atherosclerosis regression in acute coronary syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• CER-001

Snippet

Sponsor: Cerenis Therapeutics, SA | Conditions: Acute Coronary Syndromes | Phase 2 | Status: COMPLETED